Lieberman J M, Chiu S S, Wong V K, Partidge S, Chang S J, Chiu C Y, Gheesling L L, Carlone G M, Ward J I
UCLA Center for Vaccine Research, Harbor-UCLA Medical Center, Torrance, California 90502, USA.
JAMA. 1996 May 15;275(19):1499-503.
To assess the safety and immunogenicity of a bivalent serogroups A/C meningococcal oligosaccharide-protein conjugate vaccine compared with the licensed meningococcal polysaccharide vaccine.
Randomized controlled trial.
Ninety healthy 18- to 24-month-old children who were seen at a southern California Kaiser Permanente clinic.
Vaccination with either the meningococcal conjugate vaccine (at 1 of 2 dosages) or the polysaccharide vaccine, with 2 doses given 2 months apart.
Immune response to each vaccine dose as determined by measurement of serogroup-specific total antibodies by enzyme-linked immunosorbent assay (ELISA) and by assessment of serum bactericidal activity.
Both vaccines appeared to be safe, and nearly all children responded with greater than 4-fold increases in antibody levels. The 2 dosages of the conjugate vaccine induced similar antibody responses; therefore, the data for the 2 conjugate vaccine groups were combined. Following 2 doses, ELISA antibody levels against group C meningococcus were significantly higher in conjugate vaccine recipients than in polysaccharide vaccine recipients (16.66 microg/mL vs. 8.31 microgm/mL; P<.001), but antibody levels against group A were not significantly different 22.75 microg/mL vs 21.24 microg/mL; P=.70). The serum bactericidal assays showed striking differences between the conjugate and polysaccharide vaccine groups. Geometric mean serum bactericidal titers were significantly higher in conjugate vaccine recipients (755.6 vs 37.6 for group A, P<.001; 3197.9 vs 11.4 for group C, P<.001).
The immune response induced by this meningococcal oligosaccharide-protein conjugate vaccine was qualitatively different from that induced by the polysaccharide vaccine, and the antibodies it elicited provided greater functional activity.
评估二价A/C群脑膜炎球菌寡糖-蛋白结合疫苗与已获许可的脑膜炎球菌多糖疫苗相比的安全性和免疫原性。
随机对照试验。
在南加州凯撒医疗机构诊所就诊的90名18至24个月大的健康儿童。
接种脑膜炎球菌结合疫苗(两种剂量之一)或多糖疫苗,两剂间隔2个月接种。
通过酶联免疫吸附测定(ELISA)测量血清群特异性总抗体以及评估血清杀菌活性来确定对每种疫苗剂量的免疫反应。
两种疫苗似乎都安全,几乎所有儿童的抗体水平都有超过4倍的升高。结合疫苗的两种剂量诱导出相似的抗体反应;因此,将两个结合疫苗组的数据合并。接种两剂后,结合疫苗接种者中针对C群脑膜炎球菌的ELISA抗体水平显著高于多糖疫苗接种者(16.66微克/毫升对8.31微克/毫升;P<0.001),但针对A群的抗体水平无显著差异(22.75微克/毫升对21.24微克/毫升;P=0.70)。血清杀菌试验显示结合疫苗组和多糖疫苗组之间存在显著差异。结合疫苗接种者的几何平均血清杀菌效价显著更高(A群为755.6对37.6,P<0.001;C群为3197.9对11.4,P<0.001)。
这种脑膜炎球菌寡糖-蛋白结合疫苗诱导的免疫反应在质量上不同于多糖疫苗诱导的免疫反应,且其所引发的抗体具有更强的功能活性。